↓ Skip to main content

Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer

Overview of attention for article published in Cancer Research, June 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
12 news outlets
blogs
2 blogs
twitter
14 tweeters
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer
Published in
Cancer Research, June 2022
DOI 10.1158/0008-5472.can-21-3106
Pubmed ID
Authors

Kalra, Rashi, Chen, Ching Hui, Wang, Junkai, Salam, Ahmad Bin, Dobrolecki, Lacey E., Lewis, Alaina, Sallas, Christina, Yates, Clayton C., Gutierrez, Carolina, Karanam, Balasubramanyam, Anurag, Meenakshi, Lim, Bora, Ellis, Matthew J., Kavuri, Shyam M., Dobrolecki, Lacey E, Yates, Clayton C, Ellis, Matthew J, Kavuri, Shyam M

Abstract

The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent HER2 mutations have differential effects on endocrine therapy responsiveness, metastasis, and pan-HER TKI therapeutic sensitivity. The prevalence and prognostic significance may also depend on whether the HER2 mutant has arisen in the context of lobular versus ductal histology. The most highly recurrent HER2 mutant, L755S, was particularly resistant to neratinib but sensitive to the pan-HER TKI poziotinib, alone or in combination with fulvestrant. Poziotinib reduced tumor growth, diminished multi-organ metastasis, and inhibited mTOR activation more effectively than neratinib. Similar therapeutic effects of poziotinib were observed in both an engineered HER2L755S MCF7 model and a patient-derived xenograft harboring a HER2G778_P780dup mutation. Overall, these findings support the need for clinical evaluation of poziotinib for the treatment of HER2 mutant metastatic breast cancer.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Attention Score in Context

This research output has an Altmetric Attention Score of 105. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2022.
All research outputs
#309,361
of 21,749,011 outputs
Outputs from Cancer Research
#160
of 17,489 outputs
Outputs of similar age
#7,226
of 314,254 outputs
Outputs of similar age from Cancer Research
#3
of 147 outputs
Altmetric has tracked 21,749,011 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,489 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,254 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.